

Understand your cancer and treatment choices

How can Foundation Medicine® help?

Please note: This brochure provides information about Foundation Medicine services, but it does not take the place of advice from a doctor. Always speak to your doctor about your condition and available diagnostic and treatment options.




Understand your cancer

Cancer happens because of changes to the way your cells work and grow. These changes are called mutations and happen in your genes (DNA).

Each person's cancer is different because of the type and number of DNA mutations. This may affect the type of treatment you need.

- **Scenario 1:** Someone could have the same type of cancer as you (like breast cancer), but if your mutations are different then you may need different types of treatment (see Person 1 and 2 in the image below).
- **Scenario 2:** It is also possible that you may have a different type of cancer (like breast cancer or lung cancer) than someone else, but if you have the same DNA mutation then you may both need the same treatment (see Person 2 and 3 in the image below).




If you know the mutations in your cancer, it can help you and your doctor find the best treatment option that may work for you.

Understand your treatment choices

There are different types of treatments that you and your doctor may talk about. These can be:

- non-targeted therapies
- targeted therapies
- immunotherapies

See picture below for more information



By testing your cancer, your doctor can find treatment options that may work best for you. For example, if your cancer has a specific mutation, there may be targeted therapies that will work on that mutation. There may also be times when either no relevant mutation is found or there are no targeted treatment options for that cancer. Even in this case, knowing the mutations in your cancer can help treatment planning with your doctor.

How do you find possible mutations in cancer cells?

Testing your genes (genomic testing) helps find mutations in cancer cells. Genomic testing looks at the specific gene(s) that make up DNA of the cancer cells.


Genomic testing can include testing:

- one gene
- a few genes (hotspot testing)
- hundreds of genes (comprehensive genomic profiling) at a time.

All of the genomic testing choices listed are searching for cancer mutations.

Foundation Medicine® provides comprehensive genomic profiling that can help to find mutations and support treatment decisions.


SINGLE-GENE AND HOTSPOT TESTING



Single-gene testing and hotspot testing look for one or a few mutations within certain areas of your cancer cells. The mutations being looked for are chosen before testing takes place.

So, if another mutation exists outside of the one that has been chosen for testing, it will not be found.

COMPREHENSIVE GENOMIC PROFILING



Comprehensive genomic profiling searches for hundreds of mutations across a large area of your cancer cells to give you a more detailed understanding of your cancer.

Comprehensive genomic profiling looks for all possible types of mutations that may be in your cancer. This gives you a better chance of finding the mutations right away.

Foundation Medicine® offers a fuller understanding of your cancer through comprehensive genomic profiling services that can help you and your doctor find appropriate treatment for you.

There are different tests available depending on your type of cancer



Speak with your doctor to see which test might be best for your cancer type.

All solid tumours

Blood cancers and sarcomas





FOUNDATIONONE® CDx



FOUNDATIONONE® LIQUID CDx



FOUNDATIONONE® HEME



Uses a tissue sample (tissue biopsy) to test the DNA for over 300 genes

Uses a blood sample (liquid biopsy) to test the DNA for over 300 genes

Uses a tissue bone marrow or blood sample to test the DNA for over 400 genes and the RNA for over 260 genes

TISSUE BIOPSY

Your doctor will take a small sample of the tissue from your cancer site. This can be done by:

- using a needle
- through surgery
- a bone marrow biopsy
- using a small tool with a camera on one end (endoscopy).

They will use the sample to run a comprehensive genomic profiling test.

LIQUID BIOPSY

Your doctor will take a blood sample from a vein in your arm or hand. They will collect 2 tubes of blood to send to the lab for the comprehensive genomic profiling test.

What if I've already had a single gene/hotspot test?

Comprehensive genomic profiling tests like FoundationOne®CDx and FoundationOne®Liquid CDx can find mutations that single gene/hotspot testing miss. Comprehensive genomic profiling searches the cancer cells for hundreds of mutations that may not be covered by single gene/hotspot tests. Your doctor may decide to test your cancer again even if you are receiving treatment or have already been tested.


When should **FoundationOne Liquid CDx** be considered?

QUICK TREATMENT DECISION	TISSUE SAMPLE (BIOPSY) NOT POSSIBLE	TESTING FOR MUTATIONS IN YOUR BLOOD, BUT ALSO SITES WHERE YOUR CANCER HAS SPREAD (METASTASES)
FoundationOne Liquid CDx allows you and your doctor to make quicker treatment decisions by delivering your results in less than 2 weeks after your blood sample arrives at the lab.	FoundationOne Liquid CDx can be helpful: <ul style="list-style-type: none">• when a tissue biopsy is not recommended for your cancer• when the tissue sample that has been taken isn't enough to test• when a tissue biopsy might take too long or is not possible to do at the time it's needed	FoundationOne Liquid CDx will test for mutations in your blood. Your blood contains the circulating DNA from your primary tumour but also from metastases if the cancer has spread to other areas. However, the capacity to detect all tumour mutations through liquid biopsy depends on a number of physical factors.

What happens to your sample once it has been sent for testing?


Your care team will send your sample to Foundation Medicine® where it will be analyzed and reviewed by our cancer experts. A detailed report will be sent to your care team.

TUMOUR SAMPLE (TISSUE OR BLOOD SAMPLE)




Your care team sends your tissue or blood sample to Foundation Medicine® where it will be analyzed.

COMPREHENSIVE GENOMIC PROFILING



Your DNA is extracted from your sample and searched for mutations.

DATA ANALYSIS



Mutations that are found are reviewed by cancer experts who use computer technology to search for available and appropriate treatment choices using a large cancer database. Treatment choices may include targeted therapies, immunotherapies, or treatments involved in a research study.

FOUNDATION MEDICINE® REPORT



Your care team will receive a detailed report within **2 weeks** (or 3 weeks for FoundationOne®Heme) after receiving the sample at the lab.

The Foundation Medicine® database is always updated based on new research, research studies, and an increasing number of patients' genomic profiles. This helps to ensure that the Foundation Medicine® report is based on the latest scientific data.

What information will the Foundation Medicine® report provide?

Page 1 of the report provides a summary of your results, while the following pages will provide more specific details.

FOUNDATIONONE® LIQUID CDx

1 © 2019 FoundationOne. FoundationOne® Liquid CDx is a next generation sequencing (NGS) test that identifies clinically relevant genomic alterations in circulating cell-free DNA.

2 **PATIENT**
Sample, Jane
TUMOR TYPE: Lung adenocarcinoma
COUNTRY CODE: BR
REPORT DATE: 28 August 2020
ORDERED TEST #: ORD-XXXXXXX-XX

Biomarker Findings
Blood Tumor Mutational Burden - 5 Muts/Mb
Microsatellite status - Cannot Be Determined
Tumor Fraction - 13%

Genomic Findings
For a complete list of the genes tested, please refer to the Appendix.
EGFR exon 19 deletion (L747_A750>P)
TP53 R267P

3 **Therapies with Clinical Benefit**
Therapies with Lack of Response
No Clinical Trials

4 **Therapy and Clinical Trial Implications**
No therapies or clinical trials. See Biomarker Findings section.
Unable to determine Microsatellite status due to insufficient evidence of genomic instability.
Tumor fraction is an estimate of the percentage of circulating tumor DNA (ctDNA) present in a ctDNA sample based on observed copy number alterations.

3a **Therapies with Clinical Benefit (IN PATIENT)**

3b **Therapies with Clinical Benefit (IN OTHER)**

3c **10 Trials** see p. 11

EGFR - exon 19 deletion (L747_A750>P) 0.20%

Electronically signed by Julia A. Enik, M.D., Ph.D. • 45 June 2020
Julia Enik, M.D., Ph.D., Laboratory Director (CLIA 200007787)
David R. Hargrave, M.D., Ph.D., M.A., M.Sc., Laboratory Director (CLIA 300044309)
Foundation Medicine, Inc. • 1-888-980-3039

Sample Preparation: 100 Second St., 1st Floor, Cambridge, MA 02142-1000
Sample Analysis: 100 Second St., 1st Floor, Cambridge, MA 02142-1000
Post-Sequencing Analysis: 100 Second St., 1st Floor, Cambridge, MA 02142-1000
PAGE 1 of 17

- 1 Your information, your doctor's information, and details about your tissue and blood sample that was tested.
- 2 Mutation and genomic findings: a summary of the mutations and other characteristics found in your cancer cells DNA. These findings help guide treatment decisions.
- 3 Depending on the mutations identified and current scientific knowledge (like medical journal articles, clinical trial data, funded treatment options in your type of cancer), the Foundation Medicine® report may indicate:
 - a Potential therapies according to your type of cancer
 - b Therapies usually available for another type of cancer
 - c Relevant clinical trials that you and your doctor can discuss together
- 4 If your cancer has progressed, the Foundation Medicine® report will help your doctor understand what has changed and guide future treatment decisions.

Important reminders about your results



- Sometimes the test cannot be done because the sample that was taken isn't enough for testing.
- Sometimes no mutations can be found in your cancer's DNA.
- If a mutation is found, many factors affect the treatments and research studies that are available to you. The report may identify treatments and research studies that are not available in Canada.
- If no mutations were found using the FoundationOne®Liquid CDx test, your doctor may recommend the FoundationOne®CDx as another test that may help.
- The test cannot predict how your cancer will respond to treatment.

Discuss the next steps in your treatment choices with your doctor.

Please note: All genomic data are deidentified, stored securely and may be used for research and scientific purposes to help improve cancer care. For more information about data privacy, please see the Patient Authorization and Consent Form or contact your local Foundation Medicine® team.

FOUNDATIONNAVIGATE™

Customer Service Support with FoundationNavigate™

For more information on cancer testing and the Foundation Medicine® comprehensive genomic profiling services visit www.foundationmedicine.ca



FoundationNavigate™ provides Canadians with customer service and patient program support for Foundation Medicine® testing services. For general inquiries or more information on how to order a test, pricing, reimbursement navigation and financial assistance, please contact our Client Service Managers at FoundationNavigate™.

✉ FoundationNavigate@patientassistance.ca

📞 1-888-650-4835 | Monday to Friday 8AM-8PM ET

If you require this information in an accessible format, please contact Roche at 1-800-561-1759.

© 2022-2023 Foundation Medicine, Inc., Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc., used under license. Content modified by Hoffmann-La Roche Limited for Canadian use.

FoundationOne®CDx, FoundationOne®Liquid CDx, and FoundationOne®Heme are next-generation sequencing services performed by Foundation Medicine, Inc. at laboratories in the USA. Hoffmann-La Roche Limited markets these services in Canada under an exclusive license from Foundation Medicine, Inc. These services were developed, and their performance characteristics determined by Foundation Medicine. As in-house laboratory-developed tests, the services have not been submitted to Health Canada for evaluation and are not subject to Health Canada approval. Reports generated from these services are prepared by Foundation Medicine, without Hoffmann-La Roche Limited's involvement, and may include scientific information about experimental medicinal products or uses that are not approved or available in Canada.

2890E23



FOUNDATIONONE®CDx



FOUNDATIONONE®LIQUID CDx



FOUNDATIONONE®HEME



FOUNDATION
MEDICINE®



Roche